No safety issues seen in Phase 2 trial of Alzheon’s oral therapy
by |
Treatment for two years with oral ALZ-801 (valiltramiprosate) sustained cognition and lowered levels of disease-related biomarkers in people with early Alzheimer’s disease carrying one or two copies of the disease-linked APOE4 genetic variant.
These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that Alzheon’s experimental therapy preserved the hippocampus, a brain structure important for memory that is damaged first in Alzheimer’s.
Importantly, ALZ-801’s safety profile over two years continued to show no increased risk of brain swelling and bleeds, which have been seen with anti-amyloid antibody-based therapies.